title: [Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
abstract: BACKGROUND
  Pembrolizumab, a humanized monoclonal antibody IgG4 anti-PD-1, having offered promising results in patients suffering from non-small cell lung cancer metastatic and heavily pretreated.
  
  
  METHODS
  We report here the case of an unexpected good response after pembrolizumab failure obtained with paclitaxel in a 68-year-old patient with stage IV lung adenocarcinoma. Moreover, the response duration with paclitaxel was more than fourteen months.
  
  
  CONCLUSIONS
  Our case suggests a mutual potentiation of chemotherapy and immunotherapy, and raises the issue of the treatment sequence to favor.
authors: Service de pneumologie, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, Strasbourg, France. Electronic address: zapataemilie@gmail.com.
authors: E
authors: E
authors: Zapata
authors: Service de pneumologie, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, Strasbourg, France.
authors: B
authors: B
authors: Mennecier
authors: Service de pneumologie, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, Strasbourg, France.
authors: C
authors: C
authors: Leduc
authors: Service de pneumologie, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, Strasbourg, France.
authors: E
authors: E
authors: Chatron
authors: Service de pneumologie, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, Strasbourg, France.
authors: E
authors: E
authors: Quoix
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C582435:pembrolizumab; D017239:Paclitaxel
keywords: Advanced non-small-cell lung cancer; Cancer bronchique non à petites cellules avancé; Checkpoint inhibitors; Immunotherapy; Immunothérapie; Inhibiteurs des points de contrôle immunologiques; Pembrolizumab